Correspondence 0001493152-24-025392 from GT Biopharma, Inc. (GTBP)
GT Biopharma, Inc.
Date: June 27, 2024 · CIK: 0000109657 · Accession: 0001493152-24-025392
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-280326
Letter
GT Biopharma, Inc.
Marina Blvd, Suite 100
Brisbane, CA 94005
June 27, 2024
Via EDGAR Submission
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Energy & Transportation
F Street, N.E.
Washington, D.C. 20549
Attention: Tim Buchmiller
Re: GT Biopharma, Inc.
Registration Statement on Form S-1
File No. 333-280326
CIK:
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), GT Biopharma, Inc., a Delaware corporation (the “Company”), respectfully requests that the effective date of the registration statement on Form S-1 (File No. 333-280326), initially filed with the U.S. Securities and Exchange Commission on June 20, 2024 (the “Registration Statement”), be accelerated so that it will become effective at 5:30 p.m., Eastern Time, on 28 June, 2024, or as soon as practicable thereafter. In making this acceleration request, the Company acknowledges that it is aware of its obligations under the Act.
If you have any questions or comments, please contact Roger Bivans of Baker & McKenzie LLP at (214) 978 3095.
Thank you for your assistance with this matter.
Sincerely,
/s/
Michael Breen
Show Raw Text
CORRESP
1
filename1.htm
GT
Biopharma, Inc.
8000
Marina Blvd, Suite 100
Brisbane,
CA 94005
June
27, 2024
Via
EDGAR Submission
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
Office
of Energy & Transportation
100
F Street, N.E.
Washington,
D.C. 20549
Attention:
Tim Buchmiller
Re:
GT
Biopharma, Inc.
Registration
Statement on Form S-1
File
No. 333-280326
CIK:
109657
Ladies
and Gentlemen:
Pursuant
to Rule 461 under the Securities Act of 1933, as amended (the “Act”), GT Biopharma, Inc., a Delaware corporation (the “Company”),
respectfully requests that the effective date of the registration statement on Form S-1 (File No. 333-280326), initially filed with the
U.S. Securities and Exchange Commission on June 20, 2024 (the “Registration Statement”), be accelerated so that it will become
effective at 5:30 p.m., Eastern Time, on 28 June, 2024, or as soon as practicable thereafter. In making this acceleration request, the
Company acknowledges that it is aware of its obligations under the Act.
If
you have any questions or comments, please contact Roger Bivans of Baker & McKenzie LLP at (214) 978 3095.
Thank
you for your assistance with this matter.
Sincerely,
/s/
Michael Breen
Michael
Breen
Interim
Chief Executive Officer
Via
E-mail:
cc:
Roger
Bivans
Baker
& McKenzie LLP